Compare Vaxcyte Inc. Common Stock (PCVX) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Visa Inc — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Visa Inc trades at $392.94 (market cap $743.55B). The key difference: Visa Inc is far larger — about 70.7× Vaxcyte Inc. Common Stock's market cap, and Visa Inc pays a 0.68% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Visa Inc for 115 Days on average.
| PCVX | V | |
|---|---|---|
Market Cap | $10.51B | $743.55B |
Volume | 2,644,694 | 7,478,804 |
Sector | Health | Financials |
52-Week High | $73.82 | $396.06 |
52-Week Low | $40.32 | $295.52 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $9.14B | $754.13B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Visa (V) trades at $391.43, up 0.55% today, showing strong momentum near its resistance level of $392. The stock maintains bullish technical signals with consistent earnings beats in recent quarters and robust profitability metrics including 50.78% net margin and 61.79% ROE. Recent developments include the launch of Intelligent Commerce Connect for AI-powered commerce and expanded stablecoin partnerships, positioning Visa at the forefront of payment innovation.
Visa presents a compelling investment case with 85% analyst buy ratings and a $423.29 consensus price target representing 8% upside. Strong fundamentals are supported by $40B revenue and $20.1B net income for 2025, though elevated valuation ratios (P/E 33.71) and emerging fintech competition pose risks. The stock's outlook remains positive given its dominant market position and AI-driven growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
